Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update

11.08.2023 - Initial Clinical Data Readout from Ongoing Phase 1/2 Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Anticipated by End of 2023 Received $5 Million Research and Development Collaboration Milestone Payment from Merck Cash Runway into ...

Related Keywords

Canada ,United States ,Shawn Iadonato ,Robert Burns ,John Mullaly ,John Vandermosten ,Kim Drapkin ,Jacques Bouchy ,Scott Dylla ,Research Collaboration Agreement ,Hc Wainwright Co ,Zack Investment Research ,Facebook ,Investor Relations Business Development ,Kineta Inc ,Nasdaq ,Linkedin ,Lifesci Advisors ,Genentech ,Cash Runway ,Chief Executive Officer ,Investment Research ,Russell Microcap Index ,Merck Exclusive License ,Genentech Option ,License Agreement ,Statements Regarding Forward Looking ,Private Securities Litigation Reform Act ,Quarterly Report ,Months Ended June ,Private Placement ,Sci Advisors ,